CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
Identifieur interne : 000202 ( Main/Exploration ); précédent : 000201; suivant : 000203CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
Auteurs : M F Nagoor Meeran [Émirats arabes unis] ; Charu Sharma [Émirats arabes unis] ; Sameer N. Goyal [Inde] ; Sanjay Kumar [États-Unis] ; Shreesh Ojha [Émirats arabes unis]Source :
- Drug development research [ 1098-2299 ] ; 2020.
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 is a deadly disease afflicting millions. The pandemic continues affecting population due to nonavailability of drugs and vaccines. The pathogenesis and complications of infection mainly involve hyperimmune-inflammatory responses. Thus, therapeutic strategies rely on repurposing of drugs aimed at reducing infectivity and inflammation and modulate immunity favourably. Among, numerous therapeutic targets, the endocannabinoid system, particularly activation of cannabinoid type-2 receptors (CB2R) emerged as an important one to suppress the hyperimmune-inflammatory responses. Recently, potent antiinflammatory, antiviral and immunomodulatory properties of CB2R selective ligands of endogenous, plant, and synthetic origin were showed mediating CB2R selective functional agonism. CB2R activation appears to regulate numerous signaling pathways to control immune-inflammatory mediators including cytokines, chemokines, adhesion molecules, prostanoids, and eicosanoids. Many CB2R ligands also exhibit off-target effects mediating activation of PPARs, opioids, and TRPV, suggestive of adjuvant use with existing drugs that may maximize efficacy synergistically and minimize therapeutic doses to limit adverse/ side effects. We hypothesize that CB2R agonists, due to immunomodulatory, antiinflammatory, and antiviral properties may show activity against COVID-19. Based on the organoprotective potential, relative safety, lack of psychotropic effects, and druggable properties, CB2R selective ligands might make available promising candidates for further investigation.
DOI: 10.1002/ddr.21752
PubMed: 33190277
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.</title><author><name sortKey="Nagoor Meeran, M F" sort="Nagoor Meeran, M F" uniqKey="Nagoor Meeran M" first="M F" last="Nagoor Meeran">M F Nagoor Meeran</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</nlm:affiliation><country xml:lang="fr">Émirats arabes unis</country><wicri:regionArea>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain</wicri:regionArea><wicri:noRegion>Al Ain</wicri:noRegion></affiliation></author><author><name sortKey="Sharma, Charu" sort="Sharma, Charu" uniqKey="Sharma C" first="Charu" last="Sharma">Charu Sharma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</nlm:affiliation><country xml:lang="fr">Émirats arabes unis</country><wicri:regionArea>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain</wicri:regionArea><wicri:noRegion>Al Ain</wicri:noRegion></affiliation></author><author><name sortKey="Goyal, Sameer N" sort="Goyal, Sameer N" uniqKey="Goyal S" first="Sameer N" last="Goyal">Sameer N. Goyal</name><affiliation wicri:level="1"><nlm:affiliation>Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule, Maharashtra, 424 001, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule, Maharashtra, 424 001</wicri:regionArea><wicri:noRegion>424 001</wicri:noRegion></affiliation></author><author><name sortKey="Kumar, Sanjay" sort="Kumar, Sanjay" uniqKey="Kumar S" first="Sanjay" last="Kumar">Sanjay Kumar</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology, Division of Nephrology, Mayo Clinic, Rochester, Minnesota, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Division of Nephrology, Mayo Clinic, Rochester, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Ojha, Shreesh" sort="Ojha, Shreesh" uniqKey="Ojha S" first="Shreesh" last="Ojha">Shreesh Ojha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</nlm:affiliation><country xml:lang="fr">Émirats arabes unis</country><wicri:regionArea>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain</wicri:regionArea><wicri:noRegion>Al Ain</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33190277</idno><idno type="pmid">33190277</idno><idno type="doi">10.1002/ddr.21752</idno><idno type="wicri:Area/Main/Corpus">000007</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000007</idno><idno type="wicri:Area/Main/Curation">000007</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000007</idno><idno type="wicri:Area/Main/Exploration">000007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.</title><author><name sortKey="Nagoor Meeran, M F" sort="Nagoor Meeran, M F" uniqKey="Nagoor Meeran M" first="M F" last="Nagoor Meeran">M F Nagoor Meeran</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</nlm:affiliation><country xml:lang="fr">Émirats arabes unis</country><wicri:regionArea>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain</wicri:regionArea><wicri:noRegion>Al Ain</wicri:noRegion></affiliation></author><author><name sortKey="Sharma, Charu" sort="Sharma, Charu" uniqKey="Sharma C" first="Charu" last="Sharma">Charu Sharma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</nlm:affiliation><country xml:lang="fr">Émirats arabes unis</country><wicri:regionArea>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain</wicri:regionArea><wicri:noRegion>Al Ain</wicri:noRegion></affiliation></author><author><name sortKey="Goyal, Sameer N" sort="Goyal, Sameer N" uniqKey="Goyal S" first="Sameer N" last="Goyal">Sameer N. Goyal</name><affiliation wicri:level="1"><nlm:affiliation>Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule, Maharashtra, 424 001, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule, Maharashtra, 424 001</wicri:regionArea><wicri:noRegion>424 001</wicri:noRegion></affiliation></author><author><name sortKey="Kumar, Sanjay" sort="Kumar, Sanjay" uniqKey="Kumar S" first="Sanjay" last="Kumar">Sanjay Kumar</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology, Division of Nephrology, Mayo Clinic, Rochester, Minnesota, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Division of Nephrology, Mayo Clinic, Rochester, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Ojha, Shreesh" sort="Ojha, Shreesh" uniqKey="Ojha S" first="Shreesh" last="Ojha">Shreesh Ojha</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</nlm:affiliation><country xml:lang="fr">Émirats arabes unis</country><wicri:regionArea>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain</wicri:regionArea><wicri:noRegion>Al Ain</wicri:noRegion></affiliation></author></analytic><series><title level="j">Drug development research</title><idno type="eISSN">1098-2299</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The COVID-19 pandemic caused by SARS-CoV-2 is a deadly disease afflicting millions. The pandemic continues affecting population due to nonavailability of drugs and vaccines. The pathogenesis and complications of infection mainly involve hyperimmune-inflammatory responses. Thus, therapeutic strategies rely on repurposing of drugs aimed at reducing infectivity and inflammation and modulate immunity favourably. Among, numerous therapeutic targets, the endocannabinoid system, particularly activation of cannabinoid type-2 receptors (CB2R) emerged as an important one to suppress the hyperimmune-inflammatory responses. Recently, potent antiinflammatory, antiviral and immunomodulatory properties of CB2R selective ligands of endogenous, plant, and synthetic origin were showed mediating CB2R selective functional agonism. CB2R activation appears to regulate numerous signaling pathways to control immune-inflammatory mediators including cytokines, chemokines, adhesion molecules, prostanoids, and eicosanoids. Many CB2R ligands also exhibit off-target effects mediating activation of PPARs, opioids, and TRPV, suggestive of adjuvant use with existing drugs that may maximize efficacy synergistically and minimize therapeutic doses to limit adverse/ side effects. We hypothesize that CB2R agonists, due to immunomodulatory, antiinflammatory, and antiviral properties may show activity against COVID-19. Based on the organoprotective potential, relative safety, lack of psychotropic effects, and druggable properties, CB2R selective ligands might make available promising candidates for further investigation.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33190277</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-2299</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Drug development research</Title><ISOAbbreviation>Drug Dev Res</ISOAbbreviation></Journal><ArticleTitle>CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ddr.21752</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by SARS-CoV-2 is a deadly disease afflicting millions. The pandemic continues affecting population due to nonavailability of drugs and vaccines. The pathogenesis and complications of infection mainly involve hyperimmune-inflammatory responses. Thus, therapeutic strategies rely on repurposing of drugs aimed at reducing infectivity and inflammation and modulate immunity favourably. Among, numerous therapeutic targets, the endocannabinoid system, particularly activation of cannabinoid type-2 receptors (CB2R) emerged as an important one to suppress the hyperimmune-inflammatory responses. Recently, potent antiinflammatory, antiviral and immunomodulatory properties of CB2R selective ligands of endogenous, plant, and synthetic origin were showed mediating CB2R selective functional agonism. CB2R activation appears to regulate numerous signaling pathways to control immune-inflammatory mediators including cytokines, chemokines, adhesion molecules, prostanoids, and eicosanoids. Many CB2R ligands also exhibit off-target effects mediating activation of PPARs, opioids, and TRPV, suggestive of adjuvant use with existing drugs that may maximize efficacy synergistically and minimize therapeutic doses to limit adverse/ side effects. We hypothesize that CB2R agonists, due to immunomodulatory, antiinflammatory, and antiviral properties may show activity against COVID-19. Based on the organoprotective potential, relative safety, lack of psychotropic effects, and druggable properties, CB2R selective ligands might make available promising candidates for further investigation.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagoor Meeran</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Charu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Sameer N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule, Maharashtra, 424 001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hematology, Division of Nephrology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojha</LastName><ForeName>Shreesh</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7801-2966</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box - 17666, Al Ain, United Arab Emirates.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Drug Dev Res</MedlineTA><NlmUniqueID>8204468</NlmUniqueID><ISSNLinking>0272-4391</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">immunomodulators</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>15</Day><Hour>20</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33190277</ArticleId><ArticleId IdType="doi">10.1002/ddr.21752</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., … Mardinoglu, A. (2020). Current Status of COVID-19 Therapies and Drug Repositioning Applications. iScience, 23(7), 101303. https://doi.org/10.1016/j.isci.2020.101303</Citation></Reference><Reference><Citation>Bassaganya-Riera, J., Song, R., Roberts, P. C., & Hontecillas, R. (2010). PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunology, 23(4), 343-352. https://doi.org/10.1089/vim.2010.0016</Citation></Reference><Reference><Citation>Bohn, M. K., Hall, A., Sepiashvili, L., Jung, B., Steele, S., & Adeli, K. (2020). Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression. Physiology (Bethesda, MD.), 35(5), 288-301. https://doi.org/10.1152/physiol.00019.2020</Citation></Reference><Reference><Citation>Capone, V., Cuomo, V., Esposito, R., Canonico, M. E., Ilardi, F., Prastaro, M., … Santoro, C. (2020). Epidemiology, prognosis and clinical manifestation of cardiovascular disease in COVID-19. Expert Review of Cardiovascular Therapy, 8, 531-539. https://doi.org/10.1080/14779072.2020.1797491</Citation></Reference><Reference><Citation>Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016). Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host & Microbe, 19(2), 181-193. https://doi.org/10.1016/j.chom.2016.01.007</Citation></Reference><Reference><Citation>Coppola, N., Zampino, R., Bellini, G., Macera, M., Marrone, A., Pisaturo, M., … Rossi, F. (2014). Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clinical Gastroenterology and Hepatology, 12(2), 334-340. https://doi.org/10.1016/j.cgh.2013.05.008</Citation></Reference><Reference><Citation>Cristino, L., Bisogno, T., & Di Marzo, V. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature reviews. Neurology, 16(1), 9-29. https://doi.org/10.1038/s41582-019-0284-z</Citation></Reference><Reference><Citation>Du, L., Ma, Y., Liu, M., Yan, L., & Tang, H. (2017). Peroxisome proliferators activated receptor (PPAR) agonists activate hepatitis B virus replication in vivo. Virology Journal, 14(1), 96. https://doi.org/10.1186/s12985-017-0765-x</Citation></Reference><Reference><Citation>Farouk, S. S., Fiaccadori, E., Cravedi, P., & Campbell, K. N. (2020). COVID-19 and the kidney: What we think we know so far and what we don't. Journal of Nephrology, 1-6. https://doi.org/10.1007/s40620-020-00789-y</Citation></Reference><Reference><Citation>Feng, G., Zheng, K. I., Yan, Q.-Q., Rios, R. S., Targher, G., Byrne, C. D., … Zheng, M.-H. (2020). COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. Journal of Clinical and Translational Hepatology, 8(1), 1-7. https://doi.org/10.14218/JCTH.2020.00018</Citation></Reference><Reference><Citation>He, Q., Xiao, F., Yuan, Q., Zhang, J., Zhan, J., & Zhang, Z. (2019). Cannabinoid receptor 2: A potential novel therapeutic target for sepsis? Acta Clinica Belgica, 74(2), 70-74. https://doi.org/10.1080/17843286.2018.1461754</Citation></Reference><Reference><Citation>Huang, S., Zhu, B., Cheon, I. S., Goplen, N. P., Jiang, L., Zhang, R., … Sun, J. (2019). PPAR-γ in macrophages limits pulmonary inflammation and promotes host recovery following respiratory viral infection. Journal of Virology, 93(9), e00030-19. https://doi.org/10.1128/JVI.00030-19</Citation></Reference><Reference><Citation>Huffman, J. W., Hepburn, S. A., Lyutenko, N., Thompson, A. L. S., Wiley, J. L., Selley, D. E., & Martin, B. R. (2010). 1-Bromo-3-(1′,1′-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorganic & Medicinal Chemistry, 18(22), 7809-7815. https://doi.org/10.1016/j.bmc.2010.09.061</Citation></Reference><Reference><Citation>Kapellos, T. S., Taylor, L., Feuerborn, A., Valaris, S., Hussain, M. T., Rainger, G. E., … Iqbal, A. J. (2019). Cannabinoid receptor 2 deficiency exacerbates inflammation and neutrophil recruitment. FASEB Journal, 33(5), 6154-6167. https://doi.org/10.1096/fj.201802524R</Citation></Reference><Reference><Citation>Morales, P., Goya, P., & Jagerovic, N. (2018). Emerging strategies targeting CB 2 cannabinoid receptor: Biased agonism and allosterism. Biochemical Pharmacology, 157, 8-17. https://doi.org/10.1016/j.bcp.2018.07.031</Citation></Reference><Reference><Citation>Oláh, A., Szekanecz, Z., & Bíró, T. (2017). Targeting cannabinoid signaling in the immune system: “High”-ly exciting questions, possibilities, and challenges. Frontiers in Immunology, 8, 1487. https://doi.org/10.3389/fimmu.2017.01487</Citation></Reference><Reference><Citation>O'Sullivan, S. E. (2016). An update on PPAR activation by cannabinoids. British Journal of Pharmacology, 173(12), 1899-1910. https://doi.org/10.1111/bph.13497</Citation></Reference><Reference><Citation>Pacher, P., & Mechoulam, R. (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Progress in Lipid Research, 50(2), 193-211. https://doi.org/10.1016/j.plipres.2011.01.001</Citation></Reference><Reference><Citation>Pedersen, A., Zachariae, R., & Bovbjerg, D. H. (2010). Influence of psychological stress on upper respiratory infection-a meta-analysis of prospective studies. Psychosomatic Medicine, 72(8), 823-832. https://doi.org/10.1097/PSY.0b013e3181f1d003</Citation></Reference><Reference><Citation>Rajkumar, R. P. (2020). COVID-19 and mental health: A review of the existing literature. Asian Journal of Psychiatry, 52, 102066. https://doi.org/10.1016/j.ajp.2020.102066</Citation></Reference><Reference><Citation>Ramirez, S. H., Reichenbach, N. L., Fan, S., Rom, S., Merkel, S. F., Wang, X., … Persidsky, Y. (2013). Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. Journal of Leukocyte Biology, 93(5), 801-810. https://doi.org/10.1189/jlb.1012523</Citation></Reference><Reference><Citation>Rossi, F., Bellini, G., Nobili, B., Maione, S., Perrone, L., & del Giudice, E. M. (2011). Association of the cannabinoid receptor 2 (CB2) Gln63Arg polymorphism with indices of liver damage in obese children: An alternative way to the CB2 hepatoprotective properties. Hepatology (Baltimore, MD.), 54(3), 1102. https://doi.org/10.1002/hep.24440</Citation></Reference><Reference><Citation>Rossi, F., Mancusi, S., Bellini, G., Roberti, D., Punzo, F., Vetrella, S., … Perrotta, S. (2011). CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura. Haematologica, 96(12), 1883-1885. https://doi.org/10.3324/haematol.2011.045732</Citation></Reference><Reference><Citation>Sagnelli, C., Uberti-Foppa, C., Hasson, H., Bellini, G., Minichini, C., Salpietro, S., … Rossi, F. (2017). Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients. PloS One, 12(7), e0181890. https://doi.org/10.1371/journal.pone.0181890</Citation></Reference><Reference><Citation>Skolnik, P. R., Rabbi, M. F., Mathys, J.-M., & Greenberg, A. S. (2002). Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 31(1), 1-10. https://doi.org/10.1097/00126334-200209010-00001</Citation></Reference><Reference><Citation>Song, J.-W., Zhang, C., Fan, X., Meng, F.-P., Xu, Z., Xia, P., … Zhang, J.-Y. (2020). Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature Communications, 11(1), 3410. https://doi.org/10.1038/s41467-020-17240-2</Citation></Reference><Reference><Citation>Staiano, R. I., Loffredo, S., Borriello, F., Iannotti, F. A., Piscitelli, F., Orlando, P., … Marone, G. (2016). Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. Journal of Leukocyte Biology, 99(4), 531-540. https://doi.org/10.1189/jlb.3HI1214-584R</Citation></Reference><Reference><Citation>Stasiulewicz, A., Znajdek, K., Grudzień, M., Pawiński, T., & Sulkowska, J. I. (2020). A guide to targeting the endocannabinoid system in drug design. International Journal of Molecular Sciences, 21(8), 2778. https://doi.org/10.3390/ijms21082778</Citation></Reference><Reference><Citation>Tahamtan, A., Samieipoor, Y., Nayeri, F. S., Rahbarimanesh, A. A., Izadi, A., Rashidi-Nezhad, A., … Salimi, V. (2018). Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. Virulence, 9(1), 217-230. https://doi.org/10.1080/21505594.2017.1389369</Citation></Reference><Reference><Citation>Taxonera, C., Sagastagoitia, I., Alba, C., Mañas, N., Olivares, D., & Rey, E. (2020). Letter: Intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Alimentary Pharmacology & Therapeutics, 52(3), 569-570. https://doi.org/10.1111/apt.15814</Citation></Reference><Reference><Citation>Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020). The trinity of COVID-19: Immunity, inflammation and intervention. Nature Reviews Immunology, 20(6), 363-374. https://doi.org/10.1038/s41577-020-0311-8</Citation></Reference><Reference><Citation>van Niekerk, G., Mabin, T., & Engelbrecht, A.-M. (2019). Anti-inflammatory mechanisms of cannabinoids: An immunometabolic perspective. Inflammopharmacology, 27(1), 39-46. https://doi.org/10.1007/s10787-018-00560-7</Citation></Reference><Reference><Citation>Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., … Kong, A.-N. (2020). An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports, 6(3), 56-70. https://doi.org/10.1007/s40495-020-00216-7</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Inde</li><li>Émirats arabes unis</li><li>États-Unis</li></country><region><li>Minnesota</li></region></list><tree><country name="Émirats arabes unis"><noRegion><name sortKey="Nagoor Meeran, M F" sort="Nagoor Meeran, M F" uniqKey="Nagoor Meeran M" first="M F" last="Nagoor Meeran">M F Nagoor Meeran</name></noRegion><name sortKey="Ojha, Shreesh" sort="Ojha, Shreesh" uniqKey="Ojha S" first="Shreesh" last="Ojha">Shreesh Ojha</name><name sortKey="Sharma, Charu" sort="Sharma, Charu" uniqKey="Sharma C" first="Charu" last="Sharma">Charu Sharma</name></country><country name="Inde"><noRegion><name sortKey="Goyal, Sameer N" sort="Goyal, Sameer N" uniqKey="Goyal S" first="Sameer N" last="Goyal">Sameer N. Goyal</name></noRegion></country><country name="États-Unis"><region name="Minnesota"><name sortKey="Kumar, Sanjay" sort="Kumar, Sanjay" uniqKey="Kumar S" first="Sanjay" last="Kumar">Sanjay Kumar</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33190277
|texte= CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33190277" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |